Keyphrases
Alcohol Dehydrogenase
38%
Anti-EGFR Antibody
19%
Cancer Tissue
19%
Carboplatin
19%
Chemotherapy
68%
Colon Cancer
22%
Colorectal Cancer
100%
Combination Chemotherapy
19%
Confidence Interval
20%
Consensus Conference
38%
Docetaxel
28%
Docetaxel Chemotherapy
38%
Epidermal Growth Factor Receptor
39%
Epistaxis
19%
Estramustine
29%
Expression Variance
19%
Gastric Adenocarcinoma
19%
Gastric Cancer
23%
Health-related Quality of Life
19%
Hormone-sensitive Prostate Cancer
38%
KRAS mutation
23%
Liver Metastasis
26%
Localized Prostate Cancer
19%
Lymph Node
19%
Lymphadenectomy
23%
Metastasis
30%
Metastatic Adrenocortical Carcinoma
19%
Metastatic Colorectal Cancer (mCRC)
41%
Metastatic Disease
21%
Metastatic Pancreatic Cancer
23%
Methylation
19%
N-cadherin
30%
Olaparib
19%
Paclitaxel
38%
Pathological Use
19%
Phase I Clinical Trial
21%
Poor Prognosis
19%
Primary Tumor
33%
Prostate-specific Antigen
23%
Prostate-specific Antigen Doubling Time
25%
Radiosurgery
38%
Randomized Double-blind
21%
RAS Status
19%
Soft Tissue
28%
Specific Pattern
19%
Stage II Colon Cancer
23%
Thymic Enlargement
19%
Thymus
19%
Tumor
37%
Vidutolimod
19%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Toxicity
9%
Adrenal Cortex Carcinoma
19%
Adverse Event
9%
Androgen
19%
Carboplatin
19%
Castration Resistant Prostate Cancer
19%
Cetuximab
8%
Chemotherapy
76%
Clinical Study
19%
Clinical Trial
40%
Colon Cancer
27%
Colorectal Cancer
59%
Colorectal Carcinoma
19%
Disease
33%
Docetaxel
38%
Doxycycline
19%
Epidermal Growth Factor Receptor
43%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Epistaxis
19%
Estramustine
22%
Formaldehyde
19%
Ipilimumab
19%
Liver Metastasis
23%
Malignant Neoplasm
13%
Maximum Tolerated Dose
7%
Metastasis
40%
Metastatic Colorectal Cancer
45%
microRNA
19%
Morphine
13%
Neoplasm
51%
Nerve Cell Adhesion Molecule
30%
Nivolumab
19%
Olaparib
19%
Paclitaxel
38%
Pancreas Cancer
38%
Panitumumab
8%
Placebo
13%
Primary Tumor
28%
Progression Free Survival
12%
Prostate Cancer
19%
Prostate Specific Antigen
9%
Rash
19%
Recurrent Disease
19%
Skin Toxicity
19%
Solid Malignant Neoplasm
19%
Stomach Cancer
19%
Systemic Treatment
15%
Toxicity
9%
Vasopressin
38%
Volume of Distribution
7%
Medicine and Dentistry
Androgen
23%
Arm
14%
Bone Tissue
7%
BRCA Mutation
19%
BRCA1
5%
Cancer
15%
Celiac Plexus
19%
Clinical Stage
14%
Clinical Trial
19%
Colon
19%
Colon Cancer
23%
Colorectal Cancer
76%
Deterioration
5%
Disease
63%
Docetaxel
23%
Epidermal Growth Factor Receptor
23%
Estramustine
8%
Gastrectomy
38%
Gastrointestinal Cancer
19%
Gleason Score
9%
Hazard Ratio
5%
Health Care
9%
Health Status
5%
Liver Metastasis
8%
Lymph Node
35%
Medicine
19%
Metastatic Carcinoma
38%
microRNA
19%
Morphine
7%
Neoplasm
17%
Numeric Rating Scale
11%
Olaparib
19%
Oncotype DX
19%
Pancreas Cancer
31%
Placebo
13%
Primary Tumor
26%
Prostate Cancer
38%
Prostate Specific Antigen
19%
Prostatectomy
9%
Quality of Life
19%
Radiosurgery
19%
Rebound
19%
Receptor Expression
19%
Recurrent Disease
19%
Retroperitoneal Lymph Node Dissection
22%
Stomach Adenocarcinoma
19%
Stomach Cancer
20%
Surgery
8%
Systemic Therapy
8%
Thymus
19%